海思科：子公司HSK39297片获得上市许可受理通知书

Core Viewpoint - The announcement indicates that the subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. has received a notice from the National Medical Products Administration regarding the acceptance of the drug application for HSK39297, which is aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1 - HSK39297 is classified as a Class 1 chemical drug according to China's new chemical drug registration classification regulations [1] - The drug is a highly efficient selective complement factor B (FB) small molecule inhibitor developed by the company [1] - HSK39297 works by inhibiting FB activity to block the activation of the alternative pathway (AP) and the complement amplification cycle, thereby suppressing the overall activity of the complement pathway [1]